Literature DB >> 8899074

Review article: management of patients with non-responsive coeliac disease.

S O'Mahony1, P D Howdle, M S Losowsky.   

Abstract

A substantial minority of patients with coeliac disease (estimated at anything between 7 and 30%) fail to respond to treatment with a gluten-free diet. Non-responsiveness may be primary, that is when the patient fails to respond to treatment following initial diagnosis, or secondary, when a patient who has previously had a documented response to gluten exclusion becomes non-responsive to therapy. The commonest cause of non-responsiveness is continued gluten ingestion, either voluntary or inadvertent. Other causes to be considered include intolerances to dietary constituents other than gluten (e.g. milk, soya), pancreatic insufficiency, enteropathy-associated T-cell lymphoma and ulcerative jejunitis. There is some evidence that ulcerative jejunitis is, in fact, a manifestation of lymphoma. The most important steps in the management of the non-responsive coeliac patient are (a) to determine whether the patient is indeed coeliac, (b) to exclude lymphoma and (c) to establish the cause of the non-responsiveness. In those coeliac patients with no demonstrable cause for non-responsiveness, a variety of therapeutic stratagems (mostly based on small, uncontrolled studies) have been described; these include elimination diets, dietary supplementation with zinc and copper, and pharmacological therapy in the form of steroids, azathioprine and cyclosporin. In a minority of non-responsive patients, the clinical course is characterized by a rapid decline, and total parenteral nutrition is required. None of the therapies described above has been subjected to rigorous controlled studies. The precise mechanisms of non-responsiveness in coeliac patients need to be unravelled before rational therapeutic approaches can be established.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899074     DOI: 10.1046/j.1365-2036.1996.66237000.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  35 in total

1.  Pancreatic insufficiency in adult celiac disease: do patients require long-term enzyme supplementation?

Authors:  Kate E Evans; John S Leeds; Stephen Morley; David S Sanders
Journal:  Dig Dis Sci       Date:  2010-05-11       Impact factor: 3.199

Review 2.  Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management.

Authors:  Fabio Panetta; Valerio Nobili; Maria Rita Sartorelli; Raffaele Edo Papa; Francesca Ferretti; Arianna Alterio; Antonella Diamanti
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

3.  A review of rifaximin and bacterial overgrowth in poorly responsive celiac disease.

Authors:  Matthew S Chang; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

4.  Celiac disease: management of persistent symptoms in patients on a gluten-free diet.

Authors:  David H Dewar; Suzanne C Donnelly; Simon D McLaughlin; Matthew W Johnson; H Julia Ellis; Paul J Ciclitira
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

5.  New and developing therapies for celiac disease.

Authors:  Christina A Tennyson; Suzanne K Lewis; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 6.  Recent advances in the understanding of celiac disease: therapeutic implications for the management of pediatric patients.

Authors:  John H Kwon; Richard J Farrell
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 7.  Refractory celiac disease.

Authors:  Hani Abdallah; Daniel Leffler; Melinda Dennis; Ciarán P Kelly
Journal:  Curr Gastroenterol Rep       Date:  2007-10

Review 8.  Pathogenesis of Enteropathy-Associated T Cell Lymphoma.

Authors:  Udit Chander; Rebecca J Leeman-Neill; Govind Bhagat
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

9.  Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience.

Authors:  A Al-Toma; W H M Verbeek; M Hadithi; B M E von Blomberg; C J J Mulder
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

10.  Celiac crisis in an adult on immunosuppressive therapy.

Authors:  Owayed Al Shammeri; Donald R Duerksen
Journal:  Can J Gastroenterol       Date:  2008-06       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.